Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in J Immunother

Retrieve available abstracts of 28 articles:
HTML format
Text format



Single Articles


    September 2017
  1. ZECCHINI JM, Kim S, Yum K, Friedlander P, et al
    Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report.
    J Immunother. 2017 Sep 18. doi: 10.1097/CJI.0000000000000184.
    PubMed     Text format     Abstract available


    July 2017
  2. REDDY SB, Possick JD, Kluger HM, Galan A, et al
    Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
    J Immunother. 2017 Jul 21. doi: 10.1097/CJI.0000000000000181.
    PubMed     Text format     Abstract available


    June 2017
  3. PUSHKAREVSKAYA A, Neuberger U, Dimitrakopoulou-Strauss A, Enk A, et al
    Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.
    J Immunother. 2017 Jun 9. doi: 10.1097/CJI.0000000000000178.
    PubMed     Text format     Abstract available


    May 2017
  4. DIAMANTOPOULOS PT, Tsatsou K, Benopoulou O, Anastasopoulou A, et al
    Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.
    J Immunother. 2017 May 11. doi: 10.1097/CJI.0000000000000172.
    PubMed     Text format     Abstract available


    February 2017
  5. DAGOGO-JACK I, Lanfranchi M, Gainor JF, Giobbie-Hurder A, et al
    A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.
    J Immunother. 2017 Feb 17. doi: 10.1097/CJI.0000000000000159.
    PubMed     Text format     Abstract available


  6. BRICOUT M, Petre A, Amini-Adle M, Bezza W, et al
    Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma.
    J Immunother. 2017;40:77-82.
    PubMed     Text format     Abstract available


    November 2016
  7. BRIGHT R, Coventry BJ, Eardley-Harris N, Briggs N, et al
    Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years' Experience: A Meta-Analysis of 3312 Patients.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


  8. JOHNSON DB, Pectasides E, Feld E, Ye F, et al
    Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


  9. DILLER ML, Kudchadkar RR, Delman KA, Lawson DH, et al
    Exogenous IL-2 Induces FoxP3+ Th17 Cells In Vivo in Melanoma Patients.
    J Immunother. 2016;39:355-366.
    PubMed     Text format     Abstract available


  10. TAHTINEN S, Blattner C, Vaha-Koskela M, Saha D, et al
    T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFalpha Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
    J Immunother. 2016;39:343-354.
    PubMed     Text format     Abstract available


    September 2016
  11. MA Q, Zhou D, DeLyria ES, Wen X, et al
    Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


  12. DIEM S, Keller F, Ruesch R, Maillard SA, et al
    Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
    J Immunother. 2016.
    PubMed     Text format     Abstract available


  13. KROPP LM, De Los Santos JF, McKee SB, Conry RM, et al
    Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


    August 2016
  14. ENGELSTEIN R, Merims S, Eisenberg G, Cohen J, et al
    Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


    July 2016
  15. WALKER J, Smylie A, Smylie M
    An Association Between Glatiramer Acetate and Malignant Melanoma.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


    May 2016
  16. BOUDEWIJNS S, Westdorp H, Koornstra RH, Aarntzen EH, et al
    Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


    April 2016
  17. NAYAR N, Briscoe K, Fernandez Penas P
    Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma.
    J Immunother. 2016;39:149-52.
    PubMed     Text format     Abstract available


    March 2016
  18. MAUL LV, Weichenthal M, Kahler KC, Hauschild A, et al
    Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


  19. HSIEH CT, Luo YH, Chien CS, Wu CH, et al
    Induced Pluripotent Stem Cell-conditioned Medium Suppressed Melanoma Tumorigenicity Through the Enhancement of Natural-Killer Cellular Immunity.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


    January 2016
  20. ZHANG M, Graor H, Yan L, Kim J, et al
    Identification of Melanoma-reactive CD4+ T-Cell Subsets From Human Melanoma Draining Lymph Nodes.
    J Immunother. 2016;39:15-26.
    PubMed     Text format     Abstract available


  21. PARK TS, Groh EM, Patel K, Kerkar SP, et al
    Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers.
    J Immunother. 2016;39:1-7.
    PubMed     Text format     Abstract available


    November 2015
  22. KIBBI N, Ariyan S, Faries M, Choi JN, et al
    Treatment of In-Transit Melanoma With Intralesional Bacillus Calmette-Guerin (BCG) and Topical Imiquimod 5% Cream: A Report of 3 Cases.
    J Immunother. 2015;38:371-375.
    PubMed     Text format     Abstract available


  23. DUPUIS ML, Fiori V, Soriani A, Ricci B, et al
    The Human Antibody Fragment DIATHIS1 Specific for CEACAM1 Enhances Natural Killer Cell Cytotoxicity Against Melanoma Cell Lines In Vitro.
    J Immunother. 2015;38:357-370.
    PubMed     Text format     Abstract available


    July 2015
  24. ZHANG M, Graor H, Visioni A, Strohl M, et al
    T Cells Derived From Human Melanoma Draining Lymph Nodes Mediate Melanoma-specific Antitumor Responses In Vitro and In Vivo in Human Melanoma Xenograft Model.
    J Immunother. 2015;38:229-38.
    PubMed     Text format     Abstract available


    June 2015
  25. RANGANATH HA, Panella TJ
    Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma.
    J Immunother. 2015;38:211.
    PubMed     Text format     Abstract available


    May 2015
  26. LUDLOW SP, Kay N
    Delayed dermatologic hypersensitivity reaction secondary to ipilimumab.
    J Immunother. 2015;38:165-6.
    PubMed     Text format     Abstract available


    February 2015
  27. THAIPISUTTIKUL I, Chapman P, Avila EK
    Peripheral neuropathy associated with ipilimumab: a report of 2 cases.
    J Immunother. 2015;38:77-9.
    PubMed     Text format     Abstract available


    January 2015
  28. GARGETT T, Fraser CK, Dotti G, Yvon ES, et al
    BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.
    J Immunother. 2015;38:12-23.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: